China Three Gorges University, Yichang, China   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Yichang China (2000)

Organization Overview

First Clinical Trial
2014
NCT02444949
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

China Three Gorges University, Yichang, China | Chongqing Three Gorges Central Hospital | Xin-Hua Xu

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Dwarfism, Pituitary (Phase 2)

Esophageal Squamous Cell Carcinoma (Phase 2)

Heart Failure (Phase 3)

Heart Failure, Systolic (Phase 3)

Lung Neoplasms (Phase 2)

Nasopharyngeal Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 13